E
Evommune, Inc. (EVMN)
NYQ – Real Time Price. Currency in USD
22.69
-0.52 (-2.24%)
At close: May 12, 2026, 4:00 PM EDT
22.00
-0.70 (-3.08%)
Pre-market: May 13, 2026, 4:23 AM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NYQ – Real Time Price. Currency in USD
22.69
-0.52 (-2.24%)
At close: May 12, 2026, 4:00 PM EDT
22.00
-0.70 (-3.08%)
Pre-market: May 13, 2026, 4:23 AM EDT
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
| Name | Position |
|---|---|
| Dr. Daniel J. Burge M.d. | Senior Vice President of Clinical Development |
| Dr. Eugene Andrew Bauer M.D. | Co-Founder, Chief Medical Officer & Director |
| Dr. Jeegar Patel Ph.D. | Chief Scientific Officer |
| Dr. Lou Sehl Ph.D. | Senior Vice President of Technical Operations |
| Mr. Gregory S. Moss Esq. | Chief Business & Legal Officer, Corporate Secretary and Chief Compliance Officer |
| Mr. J. Mark Jackson M.D. | Senior Vice President of Clinical Development |
| Mr. Kyle Carver CPA, M.B.A. | Chief Financial Officer |
| Mr. Luis C. Pena | Founder, President, CEO & Director |
| Ms. Janice Drew M.P.H. | Chief of Development Operations |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | 10-Q | evmn-20260331.htm |
| 2026-04-21 | ARS | evmn-2026-proxy-ars.pdf |
| 2026-04-17 | S-1 | d127341ds1.htm |
| 2026-04-13 | 8-K | evmn-20260413.htm |
| 2026-03-05 | 10-K | evmn-20251231.htm |
| 2026-02-13 | 8-K | evmn-20260212.htm |
| 2026-02-10 | 8-K | evmn-20260210.htm |
| 2025-12-11 | 10-Q | evmn-20250930.htm |
| 2025-11-07 | S-8 | d78726ds8.htm |
| 2025-11-07 | 8-K | d38367d8k.htm |